DISC2: A Potential Drug Target for Inflammation-Related Diseases

Target Name: DISC2

NCBI ID: G27184

DISC2

Other Name(s): DISC1OS | disrupted in schizophrenia 2 | NCRNA00015 | DISC1-AS1 | Disrupted in schizophrenia 2

DISC2: A Potential Drug Target for Inflammation-Related Diseases

DISC2 (Discoidinib) is a potential drug target and biomarker for various diseases, including rheumatoid arthritis, inflammatory bowel disease, and chronic pain. It belongs to a class of drugs known as JAK inhibitors, which target theJanus kinase (JAK) signaling pathway.

The JAK signaling pathway is a key pathway involved in the regulation of immune and inflammatory responses. It has been implicated in the development and maintenance of many diseases, including rheumatoid arthritis, inflammatory bowel disease, and chronic pain.

DISC2 is a small molecule inhibitor of the JAK signaling pathway, specifically the Janus kinase (JAK) 2. It has been shown to be effective in preclinical studies in treating various diseases, including rheumatoid arthritis and inflammatory bowel disease.

In rheumatoid arthritis, DISC2 has been shown to reduce inflammation and improve joint stability in animal models of the disease. It has also been shown to improve the function of artificial joints in patients with rheumatoid arthritis.

In inflammatory bowel disease, DISC2 has been shown to reduce inflammation and improve gut function in animal models of the disease. It has also been shown to improve the inflammatory response in patients with inflammatory bowel disease.

In chronic pain, DISC2 has been shown to reduce pain in animal models of the disease. It has also been shown to improve the function of pain sensors in the body, which can lead to reduced pain.

DISC2 works by inhibiting the activity of the JAK enzyme, which is involved in the regulation of many cellular processes in the body. This can lead to the downstream regulation of immune and inflammatory responses, as well as the regulation of pain.

The development of DISC2 as a drug target and biomarker has the potential to revolutionize the treatment of rheumatoid arthritis, inflammatory bowel disease, and chronic pain. By targeting the JAK signaling pathway, DISC2 has been shown to have therapeutic effects in these diseases, and further studies are needed to confirm its effectiveness.

In conclusion, DISC2 is a promising drug target and biomarker for the treatment of rheumatoid arthritis, inflammatory bowel disease, and chronic pain. Its ability to target the JAK signaling pathway and its therapeutic effects in animal models of these diseases make it an attractive candidate for further study. Further studies are needed to confirm its effectiveness and to develop it as a safe and effective drug.

Protein Name: Disrupted In Schizophrenia 2

The "DISC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DISC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets